<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2304-0106</journal-id>
<journal-title><![CDATA[Anales de la Academia de Ciencias de Cuba]]></journal-title>
<abbrev-journal-title><![CDATA[Anales de la ACC]]></abbrev-journal-title>
<issn>2304-0106</issn>
<publisher>
<publisher-name><![CDATA[Academia de Ciencias de Cuba]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2304-01062021000300022</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Reposicionamiento del anticuerpo monoclonal humanizado anti-CD6 itolizumab en el tratamiento de pacientes con COVID-19]]></article-title>
<article-title xml:lang="en"><![CDATA[Reprofiling the anti-CD6 antibody for the treatment of patients with COVID-19]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Crombet Ramos]]></surname>
<given-names><![CDATA[Tania]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramos Suzarte]]></surname>
<given-names><![CDATA[Mayra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Saavedra Hernández]]></surname>
<given-names><![CDATA[Danay]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[León Monzón]]></surname>
<given-names><![CDATA[Kalet]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Betancourt Cervantes]]></surname>
<given-names><![CDATA[Julio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Filgueira Morilla]]></surname>
<given-names><![CDATA[Lázaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hidalgo Mesa]]></surname>
<given-names><![CDATA[Carlos J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz Morales]]></surname>
<given-names><![CDATA[Yayquier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mazorra Herrera]]></surname>
<given-names><![CDATA[Zaima]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lorenzo Luaces]]></surname>
<given-names><![CDATA[Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valenzuela Silva]]></surname>
<given-names><![CDATA[Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lorenzo Monteagudo]]></surname>
<given-names><![CDATA[Geydi]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cepeda Portales]]></surname>
<given-names><![CDATA[Meyán]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Caballero López]]></surname>
<given-names><![CDATA[Armando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro de Inmunología Molecular  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Militar Universitario Manuel Fajardo Rivero  ]]></institution>
<addr-line><![CDATA[ Villa Clara]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Arnaldo Milián Castro  ]]></institution>
<addr-line><![CDATA[ Villa Clara]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Titular de la Academia de Ciencias de Cuba  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>11</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S2304-01062021000300022&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S2304-01062021000300022&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S2304-01062021000300022&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: La neumonía COVID-19 puede conducir a un estado hiperinflamatorio. El CD6 es una glicoproteína expresada en linfocitos T maduros que constituye un regulador crucial de la activación de las células T. El itolizumab es un anticuerpo monoclonal que reconoce el CD6. Los datos clínicos en enfermedades autoinmunes indican que reduce múltiples citocinas proinflamatorias. Objetivo: evaluar la seguridad y el impacto de itolizumab sobre la interleucina-6, la función pulmonar y la mortalidad de los pacientes con COVID-19.  Métodos:  Se incluyeron 68 pacientes moderados, severos y críticos en un ensayo de acceso expandido en Cuba. El itolizumab se administró junto con otras terapias incluidas en el protocolo nacional para el SARS-CoV-2.  Resultados:  Todos los pacientes completaron la primera infusión y 41, recibieron 2 dosis. La mediana de edad fue de 68 años y el 94 % era portador de comorbilidades. El itolizumab mejoró la función pulmonar y fue bien tolerado; 3 sujetos tuvieron eventos adversos graves relacionados. La interleucina-6 disminuyó en individuos con niveles altos y no se incrementó en aquellos pacientes con concentraciones más bajas. La tasa de letalidad a los 14 días fue del 4 % y del 18 % para los pacientes moderados y graves. Aunque este estudio no fue aleatorizado, los datos preliminares sugieren que itolizumab redujo la probabilidad de muerte en comparación con los controles. El tiempo de tratamiento, las manifestaciones neurológicas y los biomarcadores como la razón entre neutrófilos y linfocitos, recuento de neutrófilos y la interleucina-6 se asociaron significativamente con mayor letalidad. Conclusiones. El itolizumab puede interrumpir la cascada inflamatoria y prevenir la morbilidad y mortalidad asociada al COVID-19.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  COVID-19 can lead to a hyper-inflammatory state. CD6 is a glycoprotein expressed on mature T-lymphocytes, which is a crucial regulator of the T-cell activation. Itolizumab is an antibody targeting CD6. Clinical data in autoimmune diseases indicate that it lowers multiple cytokines primarily involving the Th1/Th17 pathway. Objective: to preliminarily assess the safety and impact of itolizumab on interleukin-6, pulmonary function and mortality of COVID-19 patients.  Methods:  Sixty-eight moderate, severe and critical patients were included in an expanded-access trial in Cuba. Itolizumab was administered together with other therapies included in the national protocol for SARS-CoV-2.  Results:  All patients completed the first infusion and 41 received 2 doses. Median age was 68 and 94 % have comorbidities. Itolizumab improved the lung function and was well tolerated; 3 subjects had related serious adverse events. Interleukin-6 decreased in individuals with high levels and did not change in those with lower concentration. 14-day lethality rate was 4 % and 18 % for moderate and severe patients. Although this was not a randomized study, preliminary data suggest that itolizumab reduced the death probability in comparison to controls. Time to treatment, neurological manifestations, biomarkers like NLR, neutrophil count and interleukin-6 were significantly associated with higher lethality. Conclusions. Itolizumab can disrupt the inflammatory cascade and might prevent the COVID-19 associated morbidity and mortality.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[itolizumab]]></kwd>
<kwd lng="es"><![CDATA[COVID-19]]></kwd>
<kwd lng="es"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="es"><![CDATA[síndrome de liberación de citocinas]]></kwd>
<kwd lng="es"><![CDATA[CD6]]></kwd>
<kwd lng="es"><![CDATA[anticuerpo monoclonal]]></kwd>
<kwd lng="en"><![CDATA[itolizumab]]></kwd>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="en"><![CDATA[cytokine release syndrome]]></kwd>
<kwd lng="en"><![CDATA[CD6]]></kwd>
<kwd lng="en"><![CDATA[monoclonal antibody]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Atal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fatima]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<source><![CDATA[IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?]]></source>
<year>2020</year>
<publisher-name><![CDATA[Pharmaceut Med]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguiar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lobrinus]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Schibler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fracasso]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lardi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inside the lungs of COVID-19 disease]]></article-title>
<source><![CDATA[Int J Legal Med]]></source>
<year>2020</year>
<volume>134</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1271-4</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ackermann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Verleden]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Kuehnel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Haverich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Welte]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Laenger]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19]]></source>
<year>2020</year>
<publisher-name><![CDATA[N Engl J Med]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Carmo]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tuning T Cell Activation The Function of CD6 At the Immunological Synapse and in T Cell Responses]]></article-title>
<source><![CDATA[Curr Drug Targets]]></source>
<year>2016</year>
<volume>17</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>630-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dogra]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Uprety]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Suresh]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis]]></article-title>
<source><![CDATA[Expert Opin Biol Ther]]></source>
<year>2017</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>395-402</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lippi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchis-Gomar]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 unravelling the clinical progression of nature&amp;apos;s virtually perfect biological weapon]]></article-title>
<source><![CDATA[Ann Transl Med]]></source>
<year>2020</year>
<volume>8</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>693</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osorio]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Jondal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chow]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The anti-CD6 mAb, IOR-T1, defined a new epitope on the human CD6 molecule that induces greater responsiveness in T cell receptor/CD3-mediated T cell proliferation]]></article-title>
<source><![CDATA[Cell Immunol]]></source>
<year>1994</year>
<volume>154</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>123-33</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Aira]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic Targeting of CD6 in Autoimmune Diseases A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab]]></article-title>
<source><![CDATA[Curr Drug Targets]]></source>
<year>2016</year>
<volume>17</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>666-77</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aira]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Prada]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chico]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunological evaluation of rheumatoid arthritis patients treated with itolizumab]]></article-title>
<source><![CDATA[MAbs]]></source>
<year>2016</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>187-95</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aira]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[López-Requena]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fuentes]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Urquiza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab]]></article-title>
<source><![CDATA[MAbs]]></source>
<year>2014</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>783-93</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krupashankar]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Dogra]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Saraswat]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Budamakuntla]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sumathy]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis results of a double-blind, randomized, placebo-controlled, phase-III study]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2014</year>
<volume>71</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>484-92</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sumathy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study]]></article-title>
<source><![CDATA[]]></source>
<year>2014</year>
<volume>71</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miossec]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation]]></article-title>
<source><![CDATA[Eur J Rheumatol]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghnewa]]></surname>
<given-names><![CDATA[YG]]></given-names>
</name>
<name>
<surname><![CDATA[Fish]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jennings]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shankar-Hari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Goodbye SIRS? Innate, trained and adaptive immunity and pathogenesis of organ dysfunction]]></article-title>
<source><![CDATA[Med Klin Intensivmed Notfmed]]></source>
<year>2020</year>
<volume>115</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>10-4.14</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ge]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Critical Role of CD6highCD4+ T Cells in Driving Th1/Th17 Cell Immune Responses and Mucosal Inflammation in IBD]]></article-title>
<source><![CDATA[J Crohns Colitis]]></source>
<year>2019</year>
<volume>13</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>510-24</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loganathan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Athalye]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[SRJEoobt]]></given-names>
</name>
</person-group>
<source><![CDATA[Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poor]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
<name>
<surname><![CDATA[Ventetuolo]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Tolbert]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Chun]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Serrao]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zeidman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis]]></source>
<year>2020</year>
<publisher-name><![CDATA[Clin Transl Med]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Xiong]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The clinical course and its correlated immune status in COVID-19 pneumonia]]></article-title>
<source><![CDATA[J Clin Virol]]></source>
<year>2020</year>
<volume>127</volume>
<page-range>1043-61</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grifoni]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Valoriani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cei]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lamanna]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gelli]]></surname>
<given-names><![CDATA[AMG]]></given-names>
</name>
<name>
<surname><![CDATA[Ciambotti]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interleukin-6 as prognosticator in patients with COVID-19]]></article-title>
<source><![CDATA[J Infect]]></source>
<year>2020</year>
<volume>81</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>452-82</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Channappanavar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fehr]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Vijay]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mack]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Meyerholz]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice]]></article-title>
<source><![CDATA[Cell Host Microbe]]></source>
<year>2016</year>
<volume>19</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>181-93</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Channappanavar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fehr]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wohlford-Lenane]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Abrahante]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Mack]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>2019</year>
<volume>129</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>3625-39</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nunes Duarte-Neto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[de Almeida Monteiro]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[da Silva]]></surname>
<given-names><![CDATA[LFF]]></given-names>
</name>
<name>
<surname><![CDATA[Malheiros]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[de Oliveira]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Theodoro Filho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Pulmonary and systemic involvement of COVID-19 assessed by ultrasound-guided minimally invasive autopsy]]></source>
<year>2020</year>
<publisher-name><![CDATA[Histopathology]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dolan]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[McSorley]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Horgan]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[McMillan]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis]]></article-title>
<source><![CDATA[Sci Rep]]></source>
<year>2017</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>16717.24</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sterne]]></surname>
<given-names><![CDATA[JAC]]></given-names>
</name>
<name>
<surname><![CDATA[Murthy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Slutsky]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Villar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<collab>Group WHOREAfC-TW</collab>
<source><![CDATA[Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis]]></source>
<year>2020</year>
<publisher-name><![CDATA[JAMA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Horby]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
<name>
<surname><![CDATA[Emberson]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Mafham]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<collab>Group RC</collab>
<source><![CDATA[Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report]]></source>
<year>2020</year>
<publisher-name><![CDATA[N Engl J Med]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Waterer]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Rello]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All]]></source>
<year>2020</year>
<publisher-name><![CDATA[Infect Dis Ther]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malgie]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schoones]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Pijls]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<source><![CDATA[Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies]]></source>
<year>2020</year>
<publisher-name><![CDATA[Clin Infect Dis]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rathi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sjijome]]></surname>
<given-names><![CDATA[Kalantri]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ethics of clinical research and practice in India during the COVID-19 pandemic]]></article-title>
<source><![CDATA[]]></source>
<year>2020</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
